Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Date : 08/15/2019 @ 6:14PM
Source : Edgar (US Regulatory)
Stock : Oncbiomune Pharmaceuticals, Inc. (QB) (OBMP)
Quote : 0.1  -0.04 (-28.57%) @ 8:59PM

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

  FORM 12b-25

SEC FILE NUMBER

000-52218

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

68235A101

 

(Check one): [  ] Form 10-K [  ] Form 20-F [  ] Form 11-K [X] Form 10-Q [  ] Form 10-D [  ] Form N-SAR [  ] Form N-CSR

 

For Period Ended: June 30, 2019

 

[  ] Transition Report on Form 10-K  

 

[  ] Transition Report on Form 20-F  

 

[  ] Transition Report on Form 11-K  

 

[  ] Transition Report on Form 10-Q  

 

[  ] Transition Report on Form N-SAR  

 

For the Transition Period Ended: ______________

 

Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

OncBioMune Pharmaceuticals, Inc.

Full Name of Registrant

 

 

Former Name if Applicable

 

11441 Industriplex Blvd., Suite 190

Address of Principal Executive Office (Street and Number)

 

Baton Rouge, LA 70809

City, State and Zip Code

 

 

 

 
 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed date; and
     
[  ] (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

 

The Registrant was unable to file our quarterly report on Form 10-Q within the prescribed time period b ecause it was not able to finalize its unaudited financial statements as of and for the fiscal quarter ended June 30, 2019 without unreasonable effort and expense. That has now occurred, and the Company has now completed its procedures with respect to the Form 10-Q, which is being filed simultaneously herewith.

 

PART IV— OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification  

 

 

Andrew Kucharchuk, CFO

  225   227-2384
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
   
  Yes [X] No[  ]
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
   
  Yes [  ] No [X]
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

2
 

 

OncBioMune Pharmaceuticals, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 15, 2019 By: /s/ Andrew Kucharchuk
    Name:

Andrew Kucharchuk

    Title: Chief Financial Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)

 

3
 

 

OncBioMune Pharmaceuticals, Inc. (USOTC:OBMP)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more OncBioMune Pharmaceuticals, Inc. Charts.

OncBioMune Pharmaceuticals, Inc. (USOTC:OBMP)
Intraday Stock Chart

Today : Monday 11 November 2019

Click Here for more OncBioMune Pharmaceuticals, Inc. Charts.

Latest OBMP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.